This one cut me deep. My foundational belief in the placebo effect’s efficacy is shaken. It’ll take some more time and reading for me to fully come around to this point of view, but I am no longer going to […]
Here’s an interesting thought: “Amid the gewgaws and heavy machinery of federal health policy there sits a single, absurdly obvious lever: reclassify a low-dose statin (say, atorvastatin 10 mg or rosuvastatin 5 mg) from Rx-only to true, Walmart-checkout-aisle OTC. Pull […]
“You could call it Oura paranoia, though the phenomenon is hardly exclusive to any one product: As wearable health technology, including Apple Watches and Fitbits, have become more popular in recent years, some users have struggled with the unintended psychological […]
King was quoted saying, “Any word you have to hunt for in a thesaurus is the wrong word. There are no exceptions to this rule.” … Well, this author thinks “And that is nonsense (also bunkum, hooey, hogwash, twaddle, and […]
“There’s something strange and a little awe-inspiring about hearing someone ask for champagne on a two-hour domestic flight. … Champagne, really? … Maybe you really can take the champagne approach—not just to flying, but to everything. Maybe there are opportunities […]
“The concept that I call the surface area of success is all about creating an asymmetric likelihood of winning in the market. It is orchestrating the circumstances and context of the startup where the likelihood of success moves from highly […]
This is a nice compilation of clips. They are confident that the value will accrue to the application layer, and maybe the big AI labs will capture that market after all. “To start the session, the Partners from Sequoia presented […]
“After implementing numerous AI solutions in healthcare settings, I’ve developed healthy skepticism toward any approach claiming comprehensive insights from a single data modality. … This is where the paper represents something genuinely different from typical AI hype. … SURVPATH tackles […]
“Venture Capitalist continue to not-generate returns for their investors. Not all of them, of course (and they’re not the only ones), but as an asset class, Venture overpaid by a country mile, and now having ‘bought high,’ their only option […]
This beauty influencer just couldn’t resist trying it on. Wow. ~ learn more